Tilray Brands Stock (NASDAQ:TLRY)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.49

52W Range

$0.35 - $2.32

50D Avg

$1.39

200D Avg

$0.84

Market Cap

$1.64B

Avg Vol (3M)

$81.78M

Beta

2.13

Div Yield

-

TLRY Company Profile


Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

2,650

IPO Date

Jul 19, 2018

Website

TLRY Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMay 25May 24May 23
Cannabis Segment$330.61M$370.69M-
Distribution Revenue$271.23M$258.74M-
Wellness Business$60.48M$55.31M-
Beverage Alcohol Business$253.18M$213.61M$100.68M

Fiscal year ends in May 25 | Currency in USD

TLRY Financial Summary


May 25May 24May 23
Revenue$821.31M$788.94M$627.12M
Operating Income$-1.70B$-174.75M$-1.37B
Net Income$-2.18B$-244.98M$-1.44B
EBITDA$-1.70B$-72.84M$-889.52M
Basic EPS$-2.46$-0.33$-2.34
Diluted EPS$-2.46$-0.33$-2.34

Fiscal year ends in May 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26Oct 09, 25 | 8:30 AM
Q4 25Jul 28, 25 | 4:30 PM
Q3 25Apr 08, 25 | 8:30 AM

Peer Comparison


TickerCompany
SSIISS Innovations International, Inc.
BGMBGM Group Ltd.
QDELQuidelOrtho Corporation
HROWHarrow Health, Inc.
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
ATRCAtriCure, Inc.
ANIPANI Pharmaceuticals, Inc.
PAHCPhibro Animal Health Corporation
VRDNViridian Therapeutics, Inc.